Revenue (Tables)

3 Months Ended

Mar. 31, 2021

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended March 31,
	2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	280	$	219	$	499	$	256	$	186	$	442
Urology and Pelvic Health	257		104		361		237		95		332
Cardiac Rhythm Management	276		193		469		255		182		437
Electrophysiology	30		53		83		32		43		74
Neuromodulation	151		46		198		151		40		191
Interventional Cardiology	343		352		696		297		336		633
Peripheral Interventions	238		195		433		224		168		392
Specialty Pharmaceuticals	10		4		13		37		4		41
Net Sales	$	1,586	$	1,166	$	2,752	$	1,489	$	1,054	$	2,543

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales for the first quarter of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.

	Three Months Ended March 31,
Geographic Regions	2021		2020
U.S.	$	1,577	$	1,452
EMEA (Europe, Middle East and Africa)	604		552
APAC (Asia-Pacific)	473		409
LACA (Latin America and Canada)	85		89
Medical Devices	2,739		2,502
U.S.	10		37
International	4		4
Specialty Pharmaceuticals	13		41
Net Sales	$	2,752	$	2,543
Emerging Markets(1)	$	317	$	273

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior year amounts to conform to the current year's presentation. The revision had an immaterial impact on previously reported Emerging Markets net sales.